Emma Morris

Emma C Morris, BA MB BChir MA PhD FRCP FRCPath FMedSci

Professor of Clinical Cell and Gene Therapy, UCL Insitute of Immunity & Transplantation.

Director, Division of Infection and Immunity, UCL.

Consultant Haematologist (Haematopoietic Stem Cell Transplantation).

Lead, Adult Immunodeficiency HSCT and Gene Therapy Service.

I am a clinician scientist, clinically trained in haematology, allogeneic haematopoietic stem cell transplantation (HSCT) and cellular therapies. My current clinical practice is in HSCT, cellular and gene therapies for haematological malignancies and inherited immune deficiencies. I have developed and lead the national allogeneic HSCT centre for adults with primary immune deficiencies (PID) at the UCL Centre for Immunodeficiency and co-ordinate an international MDT to discuss the role of HSCT and gene therapy in adult PID patients.

My basic science research group focuses on T cell immunology, inherited immunodeficiencies, gene therapy and gene editing. This research spans the entire translational pathway from animal models to in vitro experimental immunology to Phase I ‘first time in man’ clinical studies.

I was appointed Director of the UCL Division of Infection and Immunity in October 2019. I am also Director of the NIHR UCLH/UCL Biomedical Research Centre Infection, Immunopathology and Immunotherapeutics (III) Theme.

I am a member of the Wellcome Trust Career Development Awards Panel. I am patron of the charity Haematology Cancer Care (HCC) which raises money for UCLH.

I am a scientific founder of a UCL Spin-out, Quell Therapeutics Ltd, which is developing gene-engineered regulatory T cells for transplant tolerance and autoimmunity.